Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-viral T-cell Therapy by Gamma Capture for High-risk Patients With Acquired or Inherited Immune Defects
NCT06027879Phase 2Enrolling by invitation
- Sponsor
- Paul Szabolcs
- Start
- Jan 2024
- Primary completion
- Jun 2028
- Modality
- Adoptive Cell Transfer
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of virus-specific T cells in adenovirus infection, cytomegalovirus infection (CMV) and Epstein-Barr virus infection, sponsored by Paul Szabolcs. Primary endpoints: Grade III-IV Acute Graft Versus Host Disease at 6 months and Clinical response to treatment of viral infection at 6 months. Started Jan 2024; status: enrolling by invitation.
02
Drugs
virus-specific T cells
03
Conditions
adenovirus infectioncytomegalovirus infection (CMV)Epstein-Barr virus infection
Beyond the preview
Go deeper on NCT06027879.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06027879.